oncnursingnews3 小时
Elacestrant Proves Effective in Advanced, Co-Mutated Breast Cancer
Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or ...
oncnursingnews8 小时
ASCO Recommends Abemaciclib for High-Risk HR+, HER2- Breast Cancer
A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain ...
oncnursingnews1 天
FDA Delays Decision Dates for Sotorasib and Obeticholic Acid
The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary ...
oncnursingnews1 天
Leuprolide, OCPs Manage Abnormal Uterine Bleeding in Stem Cell Transplant
Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.
oncnursingnews1 天
Pattie Jakel, MN, RN, AOCN
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews2 天
Jackie Miller, RN, BSN, OCN
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews2 天
Kathy Wilkinson, RN, BSN, OCN
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews2 天
Kathryn Wells, RN, MS, CPNP, CPON
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews2 天
Maria Quirch, BSN, RN, OCN
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews2 天
Hyoung Jin Kang, MD, PhD
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews4 天
Upstage Lung Cancer
Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd ...
oncnursingnews6 天
Making the Decision: Bispecifics Vs. CAR T-Cell Therapy in Myeloma
Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma. Lifestyle preferences and baseline ...